Barclays PLC Has $1.29 Million Holdings in Humacyte, Inc. (NASDAQ:HUMA)

Barclays PLC lifted its stake in shares of Humacyte, Inc. (NASDAQ:HUMA) by 177.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 236,742 shares of the company’s stock after purchasing an additional 151,458 shares during the period. Barclays PLC owned approximately 0.20% of Humacyte worth $1,288,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the company. nVerses Capital LLC bought a new position in shares of Humacyte in the 2nd quarter worth $28,000. Concurrent Investment Advisors LLC acquired a new position in shares of Humacyte in the third quarter valued at approximately $75,000. Principal Financial Group Inc. acquired a new stake in shares of Humacyte in the 2nd quarter valued at about $83,000. FORA Capital LLC bought a new stake in shares of Humacyte in the third quarter valued at about $96,000. Finally, Profund Advisors LLC acquired a new position in shares of Humacyte during the second quarter worth about $97,000. 44.71% of the stock is currently owned by institutional investors.

Insider Activity at Humacyte

In other Humacyte news, Director Brady W. Dougan sold 427,459 shares of Humacyte stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the transaction, the director now directly owns 1,992,253 shares of the company’s stock, valued at approximately $8,646,378.02. This trade represents a 17.67 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Laura E. Niklason sold 811,172 shares of the company’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $4.44, for a total transaction of $3,601,603.68. Following the sale, the chief executive officer now owns 2,419,712 shares of the company’s stock, valued at approximately $10,743,521.28. The trade was a 25.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,500,000 shares of company stock worth $6,606,799. 11.20% of the stock is owned by company insiders.

Humacyte Stock Performance

Shares of HUMA stock opened at $5.50 on Friday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.10 and a current ratio of 1.10. The firm has a market cap of $692.22 million, a price-to-earnings ratio of -4.10 and a beta of 1.38. The firm’s 50-day simple moving average is $4.77 and its two-hundred day simple moving average is $5.76. Humacyte, Inc. has a 52 week low of $2.48 and a 52 week high of $9.97.

Analysts Set New Price Targets

A number of brokerages have recently commented on HUMA. D. Boral Capital reissued a “buy” rating and issued a $25.00 price objective on shares of Humacyte in a research report on Friday, December 20th. BTIG Research reaffirmed a “buy” rating and set a $10.00 target price on shares of Humacyte in a report on Friday, October 18th. Piper Sandler set a $6.00 price target on Humacyte and gave the stock a “neutral” rating in a report on Friday, October 18th. TD Cowen restated a “buy” rating and issued a $10.00 price target on shares of Humacyte in a research note on Friday, October 18th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $13.00 price target on shares of Humacyte in a research report on Friday, September 20th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Humacyte currently has an average rating of “Buy” and an average price target of $13.71.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.